Cargando…
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
BACKGROUND: ESR1 mutations have been identified as mechanism for endocrine resistance and are also associated with a decreased overall survival. We assessed ESR1 mutations in circulating tumor DNA (ctDNA) for impact on outcome to taxane-based chemotherapy in advanced breast cancer patients. METHODS:...
Autores principales: | Bos, M. K., Lam, S. W., Motta, G., Helmijr, J. C. A., Beaufort, C. M., de Jonge, E., Martens, J. W. M., Boven, E., Jansen, M. P. H. M., Jager, A., Sleijfer, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241671/ https://www.ncbi.nlm.nih.gov/pubmed/37226020 http://dx.doi.org/10.1007/s10549-023-06965-5 |
Ejemplares similares
-
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020) -
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
por: Vitale, Silvia R., et al.
Publicado: (2022) -
ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022) -
Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences
por: Deissler, Heidrun L, et al.
Publicado: (2012) -
Paclitaxel Ameliorates Palmitate-Induced Injury in Mouse Podocytes
por: Son, Seung Seob, et al.
Publicado: (2020)